QIAGEN Breaks Ground to Expand North America Headquarters, Manufacturing Facility in Montgomery County, Maryland
County, State Officials Join QIAGEN Executives to Celebrate Launch of Expansion Project; Company to Invest in Workforce Development with Donation of State-of-the-Art Laboratory Instruments
Germantown, Maryland -- September 24, 2010 -- QIAGEN, a global biotechnology industry leader and one of Montgomery County, Maryland's prominent and fast-growing biotech companies, broke ground today for a $52 million expansion of its North American headquarters and manufacturing center in Germantown.
Ten years after the company first announced plans to build the headquarters in the heart of Montgomery County's I-270 Technology Corridor and eight years after it opened its doors in Germantown, QIAGEN executives from around the world were joined by an array of State and County officials for a groundbreaking ceremony to celebrate the expansion.
"QIAGEN has experienced rapid growth on a global basis and, as a result, we are delighted to be expanding our North American headquarters here in Maryland," said QIAGEN Chief Executive Officer Peer Schatz. "Montgomery County is truly at the epicenter of bioscience and genomics research, discovery, manufacturing and commercialization. The state and county leadership has shown great vision in fostering the growth of these industries, and of companies like QIAGEN."
"QIAGEN's growth over the past decade, witnessed by this significant expansion project, demonstrates once again why Montgomery County is such a premiere location for bioscience and technology companies," said Montgomery County Executive Isiah Leggett. "Not only is QIAGEN a true global leader, but also an outstanding corporate citizen; we applaud them on their continued job creation in the County and on their important contributions to medical science. QIAGEN is one of Montgomery County's true shining stars and their continued growth and success contributes significantly to our ongoing efforts to make the County's dynamic life sciences cluster the best in the world."
Expanding Buildings, Expanding Workforce
The leading global provider of sample and assay technologies, QIAGEN employs more than 3,500 people in over 35 locations worldwide, including nearly 700 across its three locations in Maryland: Germantown, Gaithersburg and Frederick. The 117,000-square-foot expansion on the Germantown campus will enable the company to consolidate several key manufacturing operations and accommodate an expected 90 new jobs. Among QIAGEN products to be manufactured within the expanded facility will be the company's flagship product: the digene HPV Test platform, a screening test that identifies women with high-risk human papillomavirus (HPV) infections that can cause cervical cancer. HPV testing enables diagnosis and treatment to be put in place before cervical cancer can develop.
"We're very pleased that QIAGEN, one of the world's premiere biotech companies with more than $1 billion in annual revenues, is expanding in Maryland," said Christian S. Johansson, Maryland Secretary of Business and Economic Development. "A global company, QIAGEN is another outstanding example of a Maryland success story. This expansion provides new economic opportunities and new jobs to our citizens and allows QIAGEN to continue developing cutting-edge diagnostics right here in our state."
QIAGEN has made significant investments in Maryland, with its 2007 acquisition of Gaithersburg-based Digene and its 2009 acquisition of Frederick-based SABiosciences. Over the past five years, the company has grown from a $400 million business to a global company with more than $1 billion in revenues. Its footprint at its North American headquarters in Maryland has grown similarly, with 125 employees in Maryland in 2005, to 693 today. QIAGEN continues to be a strong local source of employment, with 87 new hires in Maryland in 2009, and 59 new hires in Maryland to-date in 2010. The United States market drives almost half of QIAGEN's global sales.
The expansion project will increase the square footage on the Germantown campus from 181,800 to 300,000 for office, lab, and manufacturing operations space. It will feature the addition of a manufacturing wing and a five-story office tower. A parking deck will be built and the employee cafeteria expanded.
QIAGEN has partnered with Forrester Construction, HITT and Whiting-Turner on pre-construction activities. Partners for the construction of the manufacturing facility will be selected shortly. QIAGEN has also recently undertaken expansion projects at its global headquarters in Hilden, Germany and at its Asia-Pacific operations in Beijing, China.
Donation to Local Academic Institutions Training Tomorrow's Bioscience Employees
To give back to the local bioscience community and to help in building a skilled workforce that is educated on the use of laboratory technologies, QIAGEN announced that it will donate several of its state-of-the-art research and diagnostic instruments to biotech training labs at Montgomery College, Johns Hopkins University's Montgomery County Campus and the Universities at Shady Grove.
QIAGEN's automated instruments enable academic labs to prepare, isolate and purify biologic samples (such as blood, tissue and cells) and perform DNA and RNA analysis that standardize results and increase productivity in labs. QIAGEN's donation of instruments - a QIAcube to Montgomery College and QIAgilityto Johns Hopkins University - is valued at approximately $55,000 based on the instrument list price. The company is also in discussion with the Universities at Shady Grove to match instrumentation to lab needs there as the campus expands its offerings in biotechnology, bio-manufacturing and bio-engineering in the years ahead.
"The talent, skill, and passion of our employees are key to QIAGEN's excellence, success and value today and in the future, said Richard C. Hart, QIAGEN's Director of Human Resources. "We are pleased to offer a range of career-track jobs in areas not just in the sciences, but in manufacturing, logistics, distribution, finance, marketing and beyond. Local academic institutions offer a range of bioscience and technology courses that help ensure QIAGEN and our peers in the local Maryland biotech industry have a qualified workforce with skills needed to perform successfully in our industry." Current employment opportunities are listed on the "careers" section of http://www.qiagen.com/.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.